BioCryst Pharmaceuticals (United States)

BioCryst Pharmaceuticals is a biotechnology company developing novel oral small-molecule medicines for rare diseases. Based in Durham, North Carolina, BioCryst created ORLADEYO (berotralstat), the first oral once-daily therapy for preventing hereditary angioedema (HAE) attacks. The company’s structure-based drug design approach targets enzyme inhibitors for rare enzyme deficiency disorders and complement-mediated diseases.